---
title: "Why Is Nano-Cap Dare Bioscience Stock Trading Higher On Tuesday?"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286142403.md"
description: "Dare Bioscience, Inc. (NASDAQ:DARE) shares rose 5.95% to $2.67 following positive Phase 3 interim results for Ovaprene, a hormone-free contraceptive. The independent Data Safety Monitoring Board (DSMB) confirmed the trial could proceed without changes, showing a pregnancy rate of approximately 9% among participants. The stock is trading 7.1% above its 20-day SMA of $2.49, indicating a bullish trend, with key resistance at $2.75 and support at $2.49."
datetime: "2026-05-12T18:21:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286142403.md)
  - [en](https://longbridge.com/en/news/286142403.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286142403.md)
---

# Why Is Nano-Cap Dare Bioscience Stock Trading Higher On Tuesday?

Shares of **Dare Bioscience, Inc.** (NASDAQ:DARE) are trading higher on Tuesday as the company is reporting positive interim results from its Phase 3 clinical trial for Ovaprene, a hormone-free contraceptive.

## Dare Bioscience Ovaprene Phase 3 Interim Results

The recent interim analysis by the independent Data Safety Monitoring Board (DSMB) showed that the trial could continue without modifications, reinforcing Ovaprene’s potential as a meaningful contraceptive alternative.

The DSMB reviewed data from 339 study subjects, contributing 1,789 menstrual cycles of safety data, representing a proportion of the study’s 2,500-cycle target.

The women’s health company said the study’s findings indicated a pregnancy rate of approximately 9% among participants, consistent with prior expectations.

**Read Also: Bernie Sanders Mocks Trump Drug Price Claim, Says President 'Who Never Lies, Said He Cut Drug Prices By 400-600%'**

## DARE Technical Analysis: Key Levels And Momentum

From a technical perspective, Dare Bioscience’s stock is currently trading 7.1% above its 20-day simple moving average (SMA) of $2.49, indicating a bullish short-term trend. The Relative Strength Index (RSI) is at 53.06, suggesting that the stock is in a neutral zone, neither overbought nor oversold, which could indicate room for further upside.

-   **Key Resistance**: $2.75 — This level is significant as it aligns closely with the recent swing high, suggesting potential selling pressure.
-   **Key Support**: $2.49 — This level is important as it corresponds to the 20-day SMA, which could act as a floor for the stock.

**DARE Stock Price Activity:** Dare Bioscience shares were up 5.95% at $2.67 at the time of publication on Tuesday, according to Benzinga Pro data.

_Photo: PeopleImages.com – Yuri A via Shuttestock_

### Related Stocks

- [DARE.US](https://longbridge.com/en/quote/DARE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IHI.US](https://longbridge.com/en/quote/IHI.US.md)
- [XHE.US](https://longbridge.com/en/quote/XHE.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)

## Related News & Research

- [Radnor Capital Management LLC Has $1.65 Million Stock Holdings in West Pharmaceutical Services, Inc. $WST](https://longbridge.com/en/news/286893528.md)
- [Resona Asset Management Co. Ltd. Cuts Position in Danaher Corporation $DHR](https://longbridge.com/en/news/286897088.md)
- [RenovoRx (RNXT) Q1 2026 Earnings Transcript](https://longbridge.com/en/news/286914537.md)
- [Nexalin closes acquisition of PONM digital health platform for USD 1.3 million](https://longbridge.com/en/news/286912786.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)